Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Using Application | HR + HER2- BC patients receiving adjuvant ribociclib + AI therapy in routine clinical practice that use the web application |
| |
| Non using Application | HR + HER2- BC patients receiving adjuvant ribociclib + AI therapy in routine clinical practice that do not use the web application |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ribociclib | Drug | CDK4/6 inhibitor |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Number (%) of patients who remain on treatment with ribociclib + AI over the 12 months period | The difference between the two groups (App and non-App) in number (%) of patients who remain on treatment with ribociclib + AI over the 12 months period (excluding patients who discontinued treatment due to AE, disease relapse, or death) | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of sessions using the web application per month | To describe the rate of the web application usage in the group of patients who use the web application. | Month 1 - Month 36 |
| Total duration of sessions (in minutes) per month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with HR+ HER2- stage II-III breast cancer who have started treatment with ribociclib + AI (± GnRH agonist for premenopausal men and women) will be enrolled in the study
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Novartis Pharmaceuticals | Contact | +41613241111 | novartis.email@novartis.com | |
| Novartis Pharmaceuticals | Contact |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Recruiting | Pskov | Russia | 180000 | Russia | |
| Novartis Investigative Site |
Not provided
Not provided
Not provided
Not provided
| Letrozole |
| Drug |
Aromatase inhibitor |
|
| Anastrozole | Drug | Aromatase inhibitor |
|
To describe the rate of the web application usage in the group of patients who use the web application.
| Month 1 - Month 36 |
| Number of questions to the chatbot per month | To describe the rate of the web application usage in the group of patients who use the web application. | Month 1 - Month 36 |
| Evaluation of patient satisfaction with the application on a 0-10 visual analog scale (VAS) | Evaluation of patient satisfaction with the application on a 0-10 VAS, where 0 is for completely dissatisfied, 10 is for completely satisfied in M1, M3, M6, M12, M24, M36 | Month 1, 3, 6, 12, 24, 36 |
| Evaluation of oncologist satisfaction with the application according to a 0-10 VAS | Evaluation of oncologist satisfaction with the application according to a 0-10 VAS, where 0 is for completely dissatisfied, 10 is for completely satisfied in M1, M3, M6, M12, M24, M36 | Month 1, 3, 6, 12, 24, 36 |
| Number of patients in each response category according to the questionnaire on quality of life | The number (%) of patients in each response category (no problems, mild problems, moderate problems, severe problems, and extremely severe problems) according to the questionnaire scale (mobility, self-care, normal activities, pain/discomfort, anxiety/depression) in M1, M3, M6, M12, M24, M36 in the groups using and not using the web application | Month 1, 3, 6, 12, 24, 36 |
| VAS score according to the questionnaire on quality of life | VAS score according to the questionnaire (VAS 0-100, where 0 is the worst health state and 100 is the best health state) at M1, M3, M6, M12, M24, and M36 in both app user and non-app user groups | Month 1, 3, 6, 12, 24, 36 |
| Assessment of patient satisfaction with treatment | Assessment of patient satisfaction with treatment (VAS 0-10, where 0 is completely dissatisfied, and 10 is completely satisfied) at M3, M6, M12, M24, and M36 in both app user and non-app user groups | Month 3, 6, 12, 24, 36 |
| Dose intensity | Dose intensity (% of missed doses as assessed by the patient, except for therapy suspension due to AE) at M3, M6, M12, M24, and M36 in both app user and non-app user groups | Month 3, 6, 12, 24, 36 |
| Number of patients with adverse events (AE) | The percentage (%) of patients with AE (cumulative and depending on the severity) at M3, M6, M12, M24, and M36 in both app user and non-app user groups | Month 3, 6, 12, 24, 36 |
| Number of patients with dose reduction and/or discontinuation of ribociclib therapy due to progression, death for breast cancer, death from another cause, other AE | The percentage (%) of patients with dose reduction and/or discontinuation of ribociclib therapy due to progression, death for breast cancer, death from another cause, other AE at M3, M6, M12, M24, and M36 in both app user and non-app user groups | Month 3, 6, 12, 24, 36 |
| Number of patients by age, education, occupation, TNM (tumor, nodus, metastasis) stage, tumor grade (G), Ki67 level in both app user and non-app user groups | Proportion (%) of patients by age, education, occupation, TNM (tumor, nodus, metastasis) stage, tumor grade (G), Ki67 level in both app user and non-app user groups | Baseline |
| Recruiting |
| Moscow |
| 115304 |
| Russia |
| Novartis Investigative Site | Recruiting | Saint Petersburg | 194017 | Russia |
| Novartis Investigative Site | Recruiting | Saint Petersburg | 194291 | Russia |
| Novartis Investigative Site | Recruiting | Saint Petersburg | 197758 | Russia |
| Novartis Investigative Site | Recruiting | Sestroretsk | 197706 | Russia |
| Novartis Investigative Site | Recruiting | Ufa | 450054 | Russia |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000589651 | ribociclib |
| D000077289 | Letrozole |
| D000077384 | Anastrozole |
| ID | Term |
|---|---|
| D009570 | Nitriles |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided